Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BioCart II
- Development stage
- Phase 2
- Lead developer
- Histogenics
- Modality
- Cell Therapies
- Administration
- Surgical Implantation, Intraarticular
01
Overview
BioCart II is an autologous cell therapy product developed by ProChon Biotech for the repair of symptomatic cartilage defects in the knee. It consists of a three-dimensional fibrin-based scaffold seeded with the patient's own chondrocytes, which are expanded ex vivo. The construct is designed to be implanted into the femoral condyle to promote the formation of hyaline-like cartilage, offering a potential improvement over the standard microfracture technique. ProChon Biotech was later acquired by Histogenics, which integrated the technology into its own cartilage repair pipeline, including the related NeoCart product.
- Brand names
- BioCart II
- Other names
- BioCart II
Beyond the preview
Go deeper on BioCart II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BioCart II.